Your browser is no longer supported. Please, upgrade your browser.
CYTK Cytokinetics, Incorporated daily Stock Chart
Cytokinetics, Incorporated
Index- P/E- EPS (ttm)-2.24 Insider Own1.20% Shs Outstand59.27M Perf Week-3.61%
Market Cap1.26B Forward P/E- EPS next Y-2.34 Insider Trans-53.08% Shs Float52.03M Perf Month45.69%
Income-131.70M PEG- EPS next Q-0.57 Inst Own97.20% Short Float15.28% Perf Quarter44.89%
Sales22.20M P/S56.58 EPS this Y-8.20% Inst Trans1.02% Short Ratio8.37 Perf Half Y118.30%
Book/sh-0.77 P/B- EPS next Y-6.90% ROA-56.50% Target Price24.50 Perf Year100.09%
Cash/sh3.71 P/C5.69 EPS next 5Y15.00% ROE647.20% 52W Range7.72 - 23.04 Perf YTD98.96%
Dividend- P/FCF- EPS past 5Y-38.80% ROI-83.50% 52W High-8.38% Beta1.40
Dividend %- Quick Ratio10.90 Sales past 5Y-10.60% Gross Margin- 52W Low173.27% ATR1.30
Employees156 Current Ratio10.90 Sales Q/Q-55.30% Oper. Margin- RSI (14)64.28 Volatility6.15% 6.99%
OptionableYes Debt/Eq- EPS Q/Q-24.10% Profit Margin- Rel Volume0.49 Prev Close20.90
ShortableYes LT Debt/Eq- EarningsMay 06 AMC Payout- Avg Volume949.77K Price21.11
Recom2.00 SMA205.52% SMA5031.97% SMA20063.56% Volume469,501 Change1.00%
May-05-20Initiated Mizuho Buy $31
Apr-09-20Upgrade Morgan Stanley Equal-Weight → Overweight $25
Sep-21-18Initiated Cantor Fitzgerald Overweight
Sep-10-18Resumed Morgan Stanley Equal-Weight $10
Nov-22-17Reiterated Morgan Stanley Overweight $25 → $17
Nov-22-17Downgrade Needham Strong Buy → Buy $22 → $12
Nov-21-17Reiterated H.C. Wainwright Buy $26 → $17
Jul-31-17Initiated Morgan Stanley Overweight $24
Mar-08-17Initiated Rodman & Renshaw Buy $25
Feb-06-17Upgrade Needham Buy → Strong Buy $17 → $22
Dec-16-16Initiated Cantor Fitzgerald Overweight $21
Jul-28-16Reiterated Needham Buy $15 → $17
Nov-10-15Reiterated FBR Capital Outperform $14 → $24
Nov-09-15Reiterated ROTH Capital Buy $18 → $22
Jul-24-15Reiterated MLV & Co Buy $9 → $14
Dec-31-14Reiterated ROTH Capital Buy $13 → $18
Nov-04-14Upgrade MLV & Co Hold → Buy $9
Apr-28-14Reiterated Needham Buy $25 → $15
Apr-25-14Downgrade MLV & Co Buy → Hold $26 → $5
Jun-26-13Reiterated MLV & Co Buy $24 → $26
May-27-20 07:30AM  
May-25-20 09:36PM  
May-11-20 12:21PM  
May-08-20 08:30AM  
May-07-20 04:00PM  
May-06-20 04:00PM  
May-05-20 11:46AM  
May-04-20 05:59PM  
Apr-30-20 08:33AM  
Apr-29-20 12:34PM  
Apr-22-20 04:00PM  
Apr-14-20 07:30AM  
Apr-08-20 04:00PM  
Apr-01-20 07:32AM  
Mar-30-20 01:35PM  
Mar-20-20 04:00PM  
Mar-04-20 07:30AM  
Mar-03-20 05:15PM  
Feb-28-20 07:30AM  
Feb-26-20 08:30AM  
Feb-25-20 12:30PM  
Feb-20-20 07:30AM  
Feb-18-20 04:00PM  
Feb-13-20 12:31PM  
Feb-12-20 10:55AM  
Feb-06-20 04:30AM  
Jan-30-20 06:59AM  
Jan-22-20 07:30AM  
Jan-17-20 09:26AM  
Jan-13-20 07:30AM  
Jan-10-20 08:10PM  
Jan-06-20 07:30AM  
Jan-03-20 05:43PM  
Dec-18-19 07:30AM  
Dec-10-19 10:45AM  
Dec-09-19 10:03AM  
Dec-05-19 07:30AM  
Nov-27-19 04:00PM  
Nov-26-19 04:00PM  
Nov-18-19 09:00AM  
Nov-11-19 12:14PM  
Nov-08-19 07:30AM  
Nov-06-19 04:05PM  
Nov-05-19 07:30AM  
Nov-01-19 11:08AM  
Oct-31-19 05:15PM  
Oct-24-19 04:00PM  
Oct-17-19 10:30AM  
Oct-04-19 07:30AM  
Oct-01-19 12:10PM  
Sep-26-19 04:00PM  
Sep-25-19 07:30AM  
Sep-23-19 05:54AM  
Sep-16-19 07:30AM  
Sep-06-19 04:00PM  
Sep-03-19 04:00PM  
Sep-02-19 01:00PM  
Aug-27-19 07:30AM  
Aug-09-19 01:23AM  
Aug-08-19 08:30PM  
Aug-01-19 10:33AM  
Jul-31-19 07:30AM  
Jul-29-19 10:08AM  
Jul-26-19 09:56AM  
Jul-25-19 04:28PM  
Jul-24-19 07:30AM  
Jul-23-19 07:30AM  
Jul-22-19 04:00PM  
Jul-18-19 10:33AM  
Jul-15-19 07:30AM  
Jun-28-19 07:30AM  
Jun-27-19 01:29PM  
Jun-24-19 04:00PM  
Jun-13-19 02:40PM  
Jun-12-19 04:00PM  
May-30-19 07:30AM  
May-09-19 08:24PM  
May-08-19 04:00PM  
May-06-19 10:29AM  
May-05-19 01:11PM  
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274, a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; and AMG 594, a novel cardiac troponin activator that is in Phase I clinical trial. The company has strategic alliances with Amgen Inc. and Astellas Pharma Inc. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Blum Robert IPresident & CEOMay 29Option Exercise6.305,00031,500308,633May 29 07:45 PM
Blum Robert IPresident & CEOMay 29Sale20.105,000100,503303,633May 29 07:45 PM
HENDERSON JOHN TDirectorMay 19Option Exercise16.863,33356,1943,583May 20 05:04 PM
GAGE L PATRICKDirectorMay 18Option Exercise16.863,33356,19423,333May 20 05:04 PM
Blum Robert IPresident & CEOMay 18Option Exercise6.304,18926,391307,822May 18 07:37 PM
Blum Robert IPresident & CEOMay 18Sale22.155,000110,732303,633May 18 07:37 PM
COSTA SANTO JDirectorMay 11Option Exercise8.4929,999254,58720,000May 12 04:22 PM
COSTA SANTO JDirectorMay 11Sale19.8229,999594,6870May 12 04:22 PM
COSTA SANTO JDirectorMay 05Option Exercise6.128,33250,9924,166May 06 06:39 PM
COSTA SANTO JDirectorMay 05Sale17.008,332141,6440May 06 06:39 PM
Blum Robert IPresident & CEOMay 01Sale14.345,00071,678304,444May 01 07:06 PM
WIERENGA WENDALLDirectorApr 28Option Exercise10.249,999102,3906,666Apr 29 06:25 PM
WIERENGA WENDALLDirectorApr 28Sale16.009,999159,9840Apr 29 06:25 PM
GAGE L PATRICKDirectorMar 06Sale14.828,000118,59220,000Mar 20 03:21 PM
BVF PARTNERS L P/IL10% OwnerFeb 13Sale15.791,072,03016,923,923424,419Feb 18 06:00 PM
Blum Robert IPresident & CEOJan 15Sale12.964,95064,159224,107Jan 16 04:53 PM
Blum Robert IPresident & CEODec 16Sale10.226,00061,326229,057Dec 17 04:24 PM
BVF PARTNERS L P/IL10% OwnerDec 11Buy9.52118,4131,126,7003,617,776Dec 12 07:49 PM
BVF PARTNERS L P/IL10% OwnerDec 10Buy9.40223,6592,102,3953,557,673Dec 12 07:49 PM
Malik Fady IbrahamEVP Research & DevelopmentDec 05Sale9.801,50014,700121,350Dec 06 04:42 PM
HENDERSON JOHN TDirectorNov 19Buy8.576,00051,4276,250Jan 02 02:22 PM
Blum Robert IPresident & CEONov 15Sale8.086,00048,508235,057Nov 18 04:12 PM
Malik Fady IbrahamEVP Research & DevelopmentNov 07Sale9.981,50014,970122,850Nov 08 05:08 PM
Blum Robert IPresident & CEOOct 15Sale11.166,00066,975238,022Oct 16 05:42 PM
Malik Fady IbrahamEVP Research & DevelopmentOct 03Sale11.221,50016,830122,067Oct 04 05:13 PM
Blum Robert IPresident & CEOSep 16Sale12.746,00076,469244,022Sep 17 05:08 PM
Malik Fady IbrahamEVP Research & DevelopmentSep 05Sale13.691,50020,531123,567Sep 06 04:48 PM
Blum Robert IPresident & CEOAug 15Sale12.646,00075,815250,022Aug 16 05:45 PM
Malik Fady IbrahamEVP Research & DevelopmentAug 08Sale13.521,50020,280125,067Aug 09 05:07 PM
Blum Robert IPresident & CEOJul 15Sale10.946,00065,632256,022Jul 16 05:25 PM
Malik Fady IbrahamEVP Research & DevelopmentJul 11Sale11.261,50016,890126,567Jul 12 07:41 PM
Blum Robert IPresident & CEOJun 17Sale9.716,00058,238262,022Jun 19 04:52 PM
Malik Fady IbrahamEVP Research & DevelopmentJun 06Sale10.311,50015,463128,067Jun 07 05:37 PM